Source comparison
Is Tesamorelin Safe Side Effects: Comparison Across GH Peptides
Tesamorelin GHRH analog (pulsatile GH release) Injection site reactions (25–35%), arthralgia (15–20%), peripheral edema (10–18%) Transient insulin resistance; fasting glucose ↑ 3–8 mg/dL in 7% of users Mild to moderate; resolve within 24–48 hours 5+ years in H
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH analog (pulsatile GH release)
- Injection site reactions (25–35%), arthralgia (15–20%), peripheral edema (10–18%)
- Transient insulin resistance; fasting glucose ↑ 3–8 mg/dL in 7% of users
- Mild to moderate; resolve within 24–48 hours
- 5+ years in HIV lipodystrophy trials; discontinuation <6%
- CJC-1295
- GHRH analog (extended half-life)
- Injection site reactions (20–30%), headache (12–18%), flu-like symptoms (8–12%)
- Minimal acute impact; long-term elevation unclear
- Moderate; longer duration due to depot effect
- Limited Phase II data; no trials beyond 12 weeks
- Ipamorelin
- Ghrelin mimetic (GH secretagogue)
- Increased appetite (30–40%), water retention (10–15%), fatigue (8–12%)
- Minimal; may improve insulin sensitivity in some cohorts
- Rare (<5%)
- Short-term trials only; no long-term human data
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist (oral)
- Increased appetite (50–60%), edema (15–25%), elevated fasting glucose (10–18%)
- Significant; fasting glucose ↑ 5–15 mg/dL in 18% of users
- N/A (oral administration)
- 2-year trials in elderly; well-tolerated but metabolic monitoring required
- Assessment
- Tesamorelin offers the most favorable balance of efficacy and tolerability for visceral fat reduction. Its pulsatile GH release mimics endogenous patterns, reducing metabolic disruption compared to sustained elevation (CJC-1295) or ghrelin-driven appetite increase (Ipamorelin, MK-677). Injection site reactions are higher than ghrelin mimetics but resolve faster. Glucose impact is clinically relevant only in pre-diabetic or diabetic populations.